<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00842088</url>
  </required_header>
  <id_info>
    <org_study_id>HQP 2008-004</org_study_id>
    <nct_id>NCT00842088</nct_id>
  </id_info>
  <brief_title>Phase 1/2 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HQK-1001 Administered Daily in Patients With Sickle Cell Disease</brief_title>
  <official_title>A Randomized, Blinded, Placebo-controlled, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HQK-1001 in Subjects With Sickle Cell Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HemaQuest Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>HemaQuest Pharmaceuticals Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and tolerability of HQK-1001 administered
      for a total of 12 weeks (with one dosing break) in subjects with sickle cell disease.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety as assessed by (1) adverse events (2) laboratory values (3) vital signs, and (4) physical exam.</measure>
    <time_frame>126 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics assessed by plasma drug concentration levels.</measure>
    <time_frame>Days 0, 6, 69 and 97 post first dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics assessed by red blood cell production and induction of fetal hemoglobin.</measure>
    <time_frame>Every 2 weeks through Day 126 post first dose</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Sickle Cell Disease</condition>
  <arm_group>
    <arm_group_label>Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo capsule. Administered orally once a day on dosing days.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HQK-1001</intervention_name>
    <description>HQK-1001 capsules. 10 mg/kg, 20 mg/kg or 30 mg/kg administered once a day on dosing days.</description>
    <arm_group_label>Active</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of SCD or sickle beta thalassemia (excluding Hemoglobin C)

          -  Between 12 and 60 years of age, inclusive

          -  At least one episode of a SCD-related crisis or complication (e.g., vaso-occlusive
             crisis, acute chest syndrome, priapism) per year for an average of 3 years or one
             episode of acute chest syndrome over the prior 5 years

          -  Screening (untransfused) HbF level &gt;/= 2% as analyzed by a central laboratory

          -  If receiving hydroxyurea therapy, must be receiving a stable dose for at least 6
             months

          -  Able and willing to give informed consent

          -  If female, must have a negative serum pregnancy test within 7 days of dosing

          -  If female, must not be of childbearing potential defined as post-menopausal by at
             least 2 years or surgically sterile, or must agree to use a medically accepted form of
             contraception throughout the study

          -  If the sexual partner of a male subject is a WCBP, she must agree to use a medically
             accepted form of birth control for themselves or their partner throughout the study

          -  In the view of the Investigator, able to comply with necessary study procedures

        Exclusion Criteria:

          -  Red blood cell (RBC) transfusion within 3 months prior to beginning study medication

          -  Participation in a regular blood transfusion program

          -  More than 4 hospitalizations for acute sickle cell-related events in the previous 12
             months

          -  An acute vaso-occlusive event within 3 weeks prior to receiving first dose of study
             medication

          -  Pulmonary hypertension requiring oxygen

          -  QTc &gt; 450 msec on screening

          -  Alanine transaminase (ALT) &gt; 3X upper limit of normal (ULN)

          -  Creatinine phosphokinase (CPK) &gt; 20% above the ULN

          -  Serum creatinine &gt;1.2 mg/dL

          -  An acute illness (e.g., febrile, gastrointestinal [GI], respiratory) within 72 hours
             prior to receiving first dose of study medication

          -  History of syncope, clinically significant dysrhythmias or resuscitation from sudden
             death

          -  Chronic opiate use which, in the view of the Investigator, could confound evaluation
             of an investigational drug

          -  Current abuse of alcohol or drugs

          -  Received another investigational agent within 4 weeks, or 5 half-lives, whichever is
             longer, prior to administration of study medication

          -  Currently pregnant or breast feeding a child

          -  Known infection with HIV-1

          -  Infection with hepatitis B or hepatitis C such that patients are currently on therapy
             or will be placed on therapy during the trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan Perrine, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>HemaQuest Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Trialogic Research</name>
      <address>
        <city>Madison</city>
        <state>Alabama</state>
        <zip>35758</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital and Research Center at Oakland</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Century Clinical Research, Inc.</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Georgia</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Illinois at Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UNC Comprehensive Sickle Cell Program</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Children's Cancer Center and Hematology Service</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of the West Indies, Mona</name>
      <address>
        <city>Kingston</city>
        <state>Mona</state>
        <zip>7</zip>
        <country>Jamaica</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Jamaica</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 11, 2009</study_first_submitted>
  <study_first_submitted_qc>February 11, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 12, 2009</study_first_posted>
  <disposition_first_submitted>July 1, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>July 28, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">August 1, 2011</disposition_first_posted>
  <last_update_submitted>July 28, 2011</last_update_submitted>
  <last_update_submitted_qc>July 28, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 1, 2011</last_update_posted>
  <responsible_party>
    <name_title>Susan Perrine, M.D.</name_title>
    <organization>HemaQuest Pharmaceuticals, Inc.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

